Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 ...

BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, ...

BioCryst Pharmaceuticals (BCRX) reported preliminary, unaudited Q4 2025 ORLADEYO net revenue of $151M, up 22% Y/Y. Full-year ...

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

BioCryst Pharmaceuticals, Inc. announced that it will release its first quarter financial results for 2025 on May 5, 2025, and will hold a conference call and webcast at 8:30 a.m. ET to discuss these ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million. The increase was primarily ...

BioCryst Pharmaceuticals (NASDAQ:BCRX) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS) for a mix of cash and stock representing an implied value of $13.00 per Astria ...

The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ...

— On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS of ($0.40), non-GAAP EPS of ($0.24), excluding one-time debt ...

BioCryst Pharmaceuticals, Inc. announced the appointment of Steve Frank, a leader in healthcare investment banking, to its board of directors. Frank, who is currently the chairman of global healthcare ...

Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)- -ORLADEYO net revenue expected to be betwe ...